Andrew Vernon

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. doi request reprint Treatment of latent tuberculosis infection
    Andrew Vernon
    Division of Tuberculosis Elimination, Clinical Research Branch, Centers for Disease Control and Prevention CDC OID Office of Infectious Diseases NCHHSTP National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA 30333, USA
    Semin Respir Crit Care Med 34:67-86. 2013
  2. ncbi request reprint Lack of weight gain and relapse risk in a large tuberculosis treatment trial
    Awal Khan
    TBTC Data and Coordinating Center, Clinical and Health System Research Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Respir Crit Care Med 174:344-8. 2006
  3. doi request reprint Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana
    Zegabriel Tedla
    Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, 1600 Clifton Road NE, Mailstop E 10, Atlanta, GA 30333, USA
    Am J Respir Crit Care Med 182:278-85. 2010
  4. ncbi request reprint A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment
    Naomi N Bock
    Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 30030, USA
    Am J Respir Crit Care Med 165:1526-30. 2002
  5. ncbi request reprint Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010
    Gerald H Mazurek
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 59:1-25. 2010

Collaborators

  • Hassan Mahomed
  • Taraz Samandari
  • DEBORAH LEWINSOHN
  • Mary Samuels
  • Roland Diel
  • Luca Richeldi
  • Charles D Wells
  • Henry M Blumberg
  • Jean Pierre Zellweger
  • Susan Dorman
  • Kim Connelly Smith
  • Gerald H Mazurek
  • Zegabriel Tedla
  • Randall Reves
  • Awal Khan
  • Timothy R Sterling
  • Naomi N Bock
  • Thabisa Sibanda
  • Anthony Hawkridge
  • James Rothel
  • Tiffany Harris
  • Kathleen Moser
  • Michael Leonard
  • Stefan Goldberg
  • Oaitse Motsamai
  • Helene Calvet
  • Sandra Arend
  • Samba Nyirenda
  • Stephen Kralovic
  • Neil Schluger
  • Jeffery Starke
  • Lisa Keep
  • John Jereb
  • Edward Nardell
  • Tefera Agizew
  • Masae Kawamura
  • Paul Barnicott
  • Masa Narita
  • John Seggerson
  • Freddie Poole
  • Phillip Lobue
  • Charles Daley
  • Peter Wrighton-Smith
  • Reggio Emilia
  • Kenneth Castro
  • Gerald Mazurek
  • Gail Woods
  • Crandall Peeler
  • John Bernardo
  • David Warshauer
  • Philip Hill
  • Edward Graviss
  • Richard O'Brien
  • C Robert Horsburgh
  • Connie Pachucki
  • Ann Mosher
  • Donna S Conwell
  • Yong Cheng Wang
  • Carol D Hamilton

Detail Information

Publications5

  1. doi request reprint Treatment of latent tuberculosis infection
    Andrew Vernon
    Division of Tuberculosis Elimination, Clinical Research Branch, Centers for Disease Control and Prevention CDC OID Office of Infectious Diseases NCHHSTP National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA 30333, USA
    Semin Respir Crit Care Med 34:67-86. 2013
    ....
  2. ncbi request reprint Lack of weight gain and relapse risk in a large tuberculosis treatment trial
    Awal Khan
    TBTC Data and Coordinating Center, Clinical and Health System Research Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Respir Crit Care Med 174:344-8. 2006
    ..Readily identified markers of tuberculosis relapse risk are needed, particularly in resource-limited settings. The association between weight gain or loss during antituberculosis therapy and relapse has not been well studied...
  3. doi request reprint Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana
    Zegabriel Tedla
    Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, 1600 Clifton Road NE, Mailstop E 10, Atlanta, GA 30333, USA
    Am J Respir Crit Care Med 182:278-85. 2010
    ..Little is known about the incidence of isoniazid-associated hepatitis in HIV-infected Africans who receive both isoniazid preventive therapy (IPT) and antiretroviral therapy (ART)...
  4. ncbi request reprint A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment
    Naomi N Bock
    Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 30030, USA
    Am J Respir Crit Care Med 165:1526-30. 2002
    ..Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted...
  5. ncbi request reprint Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010
    Gerald H Mazurek
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 59:1-25. 2010
    ..Specific areas needing additional research are listed...